What was the overall market valuation of the US multiple myeloma-treatment market in 2024?

The overall market valuation was $2700.0 Million in 2024. Read More

What is the projected market valuation for the US multiple myeloma-treatment market by 2035?

The projected market valuation for 2035 is $4500.0 Million. Read More

What is the expected CAGR for the US multiple myeloma-treatment market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 4.75%. Read More

Which companies are considered key players in the US multiple myeloma-treatment market?

Key players include Bristol Myers Squibb, Johnson & Johnson, Amgen, Novartis, Takeda, Celgene, AbbVie, and Sanofi. Read More

What were the revenue ranges for chemotherapy in the US multiple myeloma-treatment market?

Chemotherapy revenue ranged from $810.0 Million to $1350.0 Million. Read More

How does the revenue for immunotherapy compare to that of targeted therapy in the market?

Immunotherapy revenue also ranged from $810.0 Million to $1350.0 Million, while targeted therapy ranged from $675.0 Million to $1125.0 Million. Read More

What is the revenue range for first-line treatment in the US multiple myeloma-treatment market?

First-line treatment revenue ranged from $1350.0 Million to $2250.0 Million. Read More

What are the revenue projections for intravenous administration in the market?

Intravenous administration is projected to generate revenue between $1350.0 Million and $2250.0 Million. Read More

Which end-user segment had the highest revenue in the US multiple myeloma-treatment market?

Hospitals had the highest revenue, ranging from $1350.0 Million to $2250.0 Million. Read More

What is the revenue range for subsequent treatment in the US multiple myeloma-treatment market?

Subsequent treatment revenue ranged from $180.0 Million to $450.0 Million. Read More

US Multiple Myeloma Treatment Market

ID: MRFR/Pharma/13139-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Multiple Myeloma Treatment Market Research Report: Size, Share, Trend Analysis By Drug Type (Chemotherapy, Immunotherapy, Targeted Therapy, Steroids), By Treatment Line (First-Line Treatment, Second-Line Treatment, Third-Line Treatment, Subsequent Treatment), By Route of Administration (Oral, Intravenous, Subcutaneous) and By End Users (Hospitals, Specialty Clinics, Research Institutes) - Growth Outlook & Industry Forecast 2025 To 2035

US Multiple Myeloma Treatment Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Type (USD Million)
  1. 4.1.1 Chemotherapy
  2. 4.1.2 Immunotherapy
  3. 4.1.3 Targeted Therapy
  4. 4.1.4 Steroids
2. 4.2 Life Sciences, BY Treatment Line (USD Million)
  1. 4.2.1 First-Line Treatment
  2. 4.2.2 Second-Line Treatment
  3. 4.2.3 Third-Line Treatment
  4. 4.2.4 Subsequent Treatment
3. 4.3 Life Sciences, BY Route of Administration (USD Million)
  1. 4.3.1 Oral
  2. 4.3.2 Intravenous
  3. 4.3.3 Subcutaneous
4. 4.4 Life Sciences, BY End-user (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Specialty Clinics
  3. 4.4.3 Research Institutes
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bristol Myers Squibb (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Johnson & Johnson (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Amgen (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Takeda (JP)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Celgene (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AbbVie (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sanofi (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY TREATMENT LINE
4. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 US MARKET ANALYSIS BY END-USER
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY TREATMENT LINE, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY TREATMENT LINE, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY END-USER, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY END-USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT LINE, 2025-2035 (USD Million)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.2.4 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Life Sciences Market Segmentation

Life Sciences By Type (USD Million, 2025-2035)

Chemotherapy
Immunotherapy
Targeted Therapy
Steroids

Life Sciences By Treatment Line (USD Million, 2025-2035)

First-Line Treatment
Second-Line Treatment
Third-Line Treatment
Subsequent Treatment

Life Sciences By Route of Administration (USD Million, 2025-2035)

Oral
Intravenous
Subcutaneous

Life Sciences By End-user (USD Million, 2025-2035)

Hospitals
Specialty Clinics
Research Institutes

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓